Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressing cancer that responds poorly to immunotherapies. Intratumoral tertiary lymphoid structures (TLS) have been associated with rare long-term PDAC survivors, but the role of TLS in PDAC and ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, becoming a standard approach for various tumor types. Consequently, accurately predicting their efficacy has become crucial in clinical practice. Artificial intelligence (AI) h...
Neoantigens exhibit high immunogenic potential and confer a uniqueness to tumor cells, making them ideal targets for personalized cancer immunotherapy. Neoantigens originate from tumor-specific genetic alterations, abnormal viral infections, or other...
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide, with a 5-year survival rate below 20 %. Immunotherapy, particularly immune checkpoint blockade (ICB)-based therapies, has bec...
The 16th annual Frontiers in Cancer Science conference convened leading experts to discuss the latest developments in cancer research. Key research themes included mechanisms of treatment resistance and innovative strategies to target resistant cance...
Journal of the American Medical Informatics Association : JAMIA
Aug 1, 2025
OBJECTIVES: Immunotherapies have revolutionized the landscape of cancer treatments. However, our understanding of response patterns in advanced cancers treated with immunotherapy remains limited. By leveraging routinely collected noninvasive longitud...
PURPOSE: This study aims to develop and validate a multiregional radiomics model to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC), and further evaluate the performance of the mode...
Wnt signaling is important in embryonic development and tumorigenesis. These biological effects can be exerted by the activation of the β-catenin-dependent canonical pathway or the β-catenin-independent non-canonical pathway. DKK1 is a potent inhibit...
Biochemical and biophysical research communications
Jul 22, 2025
The direction of anticancer therapies has changed in recent years, including the increasing use of immunotherapy. However, around 50 % of non-small-cell lung cancer (NSCLC) patients do not respond to immunotherapy. Therefore, it is important to find ...
The global cancer care burden is projected to reach $25 trillion by 2050, with the United States experiencing increasing costs from $57 billion to $209 billion. The application of expensive cellular immunotherapies (exceeding $300,000 per treatment) ...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.